Opinion/decision on a Paediatric investigation plan (PIP): Bosulif, Bosutinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Oncology, PIP number: P/0336/2023

Opinion/decision on a Paediatric investigation plan (PIP): Benlysta, belimumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Immunology-Rheumatology-Transplantation, PIP number: P/0395/2022

Antimicrobial Sales and Use (ASU) Platform: Release notes

EMEA-002326-PIP04-20-M01

Opinion/decision on a Paediatric investigation plan (PIP): Kaftrio, elexacaftor,tezacaftor,ivacaftor, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Other, PIP number: P/0392/2023

EMEA-002310-PIP01-17-M01

Opinion/decision on a Paediatric investigation plan (PIP): Ultomiris, ravulizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Uro-nephrology, PIP number: P/0353/2023

Opinion/decision on a Paediatric investigation plan (PIP): Tavneos, Avacopan, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Immunology-Rheumatology-Transplantation, PIP number: P/0352/2023

Opinion/decision on a Paediatric investigation plan (PIP): Ultomiris, ravulizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Uro-nephrology, PIP number: P/0379/2023

Opinion/decision on a Paediatric investigation plan (PIP): Ajovy, fremanezumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Neurology, PIP number: P/0378/2023